Recommendations for management of patients with neuroendocrine liver metastases (Q38175261)

30 August 2017

Recommendations for management of patients with neuroendocrine liver metastases (English)

1 reference

30 August 2017

Riad Salem

6

0 references

Mickaël Lesurtel

0 references

author name string

Andrea Frilling

1

1 reference

30 August 2017

Irvin M Modlin

2

1 reference

30 August 2017

Mark Kidd

3

1 reference

30 August 2017

Christopher Russell

4

1 reference

30 August 2017

Stefan Breitenstein

5

1 reference

30 August 2017

Dik Kwekkeboom

7

1 reference

30 August 2017

Wan-yee Lau

8

1 reference

30 August 2017

Catherine Klersy

9

1 reference

30 August 2017

Valerie Vilgrain

10

1 reference

30 August 2017

Brian Davidson

11

1 reference

30 August 2017

Mark Siegler

12

1 reference

30 August 2017

Martyn Caplin

13

1 reference

30 August 2017

Enrico Solcia

14

1 reference

30 August 2017

Richard Schilsky

15

1 reference

30 August 2017

Working Group on Neuroendocrine Liver Metastases

16

1 reference

30 August 2017

1 January 2014

1 reference

Lancet Oncology Commission

30 August 2017

1 reference

30 August 2017

15

1 reference

30 August 2017

e8-21

1 reference

30 August 2017

1

1 reference

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Prognostic variables in patients with gastrointestinal carcinoid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Prognostic factors in gastrointestinal endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Going from evidence to recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Survival and prognostic factors in patients with small bowel carcinoid tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Different gene expression profiles in metastasizing midgut carcinoid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Circulating tumor cells as prognostic markers in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echo-enhanced ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Characterization of microvascularization of liver tumor lesions with high resolution linear ultrasound and contrast enhanced ultrasound (CEUS) during surgery: First results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think...

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Treatment options for unresectable neuroendocrine liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Long-term survival after surgical management of neuroendocrine hepatic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Systemic treatment of neuroendocrine tumors with hepatic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Hepatic neuroendocrine metastases: chemo- or bland embolization?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Selective internal radiation therapy-induced extrahepatic injury: an emerging cause of iatrogenic organ damage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

Clinical trials in the era of personalized oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970362-0

7 January 2021

10.1016/S1470-2045(13)70362-0

Identifiers

DOI

1 reference

30 August 2017

1 reference